LAVA Therapeutics N.V.
LVTX
$1.54
$0.0251.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1,313.60% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 1,313.60% | -- | -- |
| Cost of Revenue | -- | -- | -24.95% | -- | -- |
| Gross Profit | -- | -- | 39.56% | -- | -- |
| SG&A Expenses | -37.41% | 1.54% | 21.84% | -2.55% | -7.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.08% | -15.95% | 37.90% | 4.68% | -49.73% |
| Operating Income | 50.08% | -272.69% | 42.75% | -5.20% | 30.65% |
| Income Before Tax | -4.30% | -503.71% | 43.52% | -38.86% | 34.83% |
| Income Tax Expenses | -16.28% | 226.09% | 874.36% | 92.00% | -11.34% |
| Earnings from Continuing Operations | -4.08% | -472.20% | 37.92% | -39.16% | 34.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.08% | -472.20% | 37.92% | -39.16% | 34.65% |
| EBIT | 50.08% | -272.69% | 42.75% | -5.20% | 30.65% |
| EBITDA | 49.52% | -295.40% | 42.47% | -5.62% | 30.76% |
| EPS Basic | -3.81% | -470.04% | 38.13% | -36.27% | 35.96% |
| Normalized Basic EPS | 27.59% | -1,459.52% | 104.85% | -35.95% | 36.11% |
| EPS Diluted | -3.81% | -470.04% | 38.13% | -36.27% | 35.96% |
| Normalized Diluted EPS | 27.59% | -1,459.52% | 104.85% | -35.95% | 36.11% |
| Average Basic Shares Outstanding | 0.29% | 0.37% | 0.36% | 2.12% | 2.03% |
| Average Diluted Shares Outstanding | 0.29% | 0.37% | 0.36% | 2.12% | 2.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |